Sales & Earnings In Brief
Prestige's OTC brands grow: Prestige Brands Holdings reports flat quarterly net sales - $73.2 million compared to $73.5 million in the year-ago period - during its Aug. 5 fiscal 2010 first-quarter earnings call. While the Irvington, N.Y.-based firm's household product revenues declined by 5 percent, its over-the-counter revenues were at $40.3 million, a 3 percent increase from the previous Q1. Increases in Chloraseptic, Clear Eyes, Little Remedies, The Doctor's and Allergen Block brands drove sales. The Little Remedies pediatrics line was up 40 percent and The Doctor's dental devices rose 47 percent, CEO Mark Pettie said during the call. The firm reported increased sales of Cutex nail polish remover, which were "partially offset by a decline on Denorex shampoo." Net income for the quarter was $8.3 million, a 6.4 percent boost from the previous year's $7.8 million, which the firm attributed mainly to a lower interest expense of $5.7 million for the quarter, $3 million lower than first quarter 2008
More from Archive
More from Pink Sheet
PharmaMar, which wants to use the Jazz Pharmaceuticals-partnered drug, lurbinectedin, in combination with Roche’s Tecentriq for treating extensive-stage small cell lung cancer, is one of two companies that this month sought an accelerated assessment of their planned EU marketing applications.
The European Medicines Agency’s chief, Emer Cooke, explained how the agency could help companies with their drug development plans, and said the EU Health Technology Assessment Regulation would help companies design clinical trials that are fit for regulators and HTA bodies.
Failing to meet the 29 April user fee date for the Barth syndrome treatment, and CDER’s request for a delay in responding to Vanda’s appeal of a tradipitant complete response letter, suggest a slowdown in review work due to layoffs and other recent changes.